Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-17-043850
Filing Date
2017-07-05
Accepted
2017-07-05 21:30:33
Documents
2
Period of Report
2017-07-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1602
2 POA DOCUMENT poa.txt EX-24.3_735372 3127
  Complete submission text file 0001209191-17-043850.txt   6060
Mailing Address 3338 LANCASHIRE RD FURLONG PA 18925
Business Address
Rowland Charles A Jr (Reporting) CIK: 0001383292 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37355 | Film No.: 17950732

Mailing Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Business Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 858-704-4660
Viking Therapeutics, Inc. (Issuer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations